Connect Portal

  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
  • About
    • About
    • Leadership
    • News
    • Careers
    • Forms
    • Contact

Tumor Genetics & Cancer Research

by Felicia Lenzo | Nov 30, 2016 | News

Dr. Lucio Miele from LSU School of Medicine talks about the benefits of the recent partnership with OmniSeq on WVUE FOX 8 News in New...

OmniSeq Forms Clinical Evaluation Partnership with LSU Health New Orleans to Provide Comprehensive Genomic Profiling

by Felicia Lenzo | Nov 10, 2016 | News

NEW ORLEANS, LOUISANA – November 10, 2016 – Louisiana State University Health Sciences Center New Orleans ( LSU Health New Orleans) and Omniseq (OmniSeq®), a subsidiary of the Roswell Park Cancer Institute (RPCI), are now partnering to provide oncologists with...

OmniSeq Presents Benefits of Immune Cancer Profiling at Association of Molecular Pathology (AMP) with Thermo Fisher Scientific

by Felicia Lenzo | Nov 10, 2016 | News

THERMO FISHER SCIENTIFIC (TMO) EXPANDS PORTFOLIO OF NEXT-GENERATION SEQUENCING CANCER RESEARCH ASSAYS New Oncomine products enable immune response analysis of the tumor microenvironment, interrogation of BRCA 1-2 genes, and liquid biopsy research using cell-free DNA...

OmniSeq Appoints Genomics Industry Veteran Mark Gardner as CEO and Board of Directors Member

by Felicia Lenzo | May 29, 2016 | News

BUFFALO, N.Y., March 31, 2016 /PRNewswire/ — OmniSeq LLC today announced the appointment of biotech industry veteran Mark Gardner as CEO and member of its Board of Directors. His role will be effective in April after he transitions from his executive management post...

OmniSeq Aims to Change the Landscape of Cancer Treatment Through Unparalleled Diagnostic Precision, Therapeutic Knowledge and Peer-to-Peer Collaboration

by Felicia Lenzo | Sep 10, 2015 | News

OmniSeq℠ Aims to Change the Landscape of Cancer Treatment Through Unparalleled Diagnostic Precision, Therapeutic Knowledge and Peer-to-Peer Collaboration Buffalo, NY – June 11, 2015 – OmniSeq, LLC today announced that it has officially begun its spin out from Roswell...
« Older Entries

Follow Us on Twitter

OmniSeq Follow

Finding the right drug or the right trial...for every #cancer patient. #immunotherapy Pronounced OmniSeek

Avatar
Avatar OmniSeq @omniseq ·
3 Jun

LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine

Reply on Twitter 1532751537994342401 Retweet on Twitter 1532751537994342401 Like on Twitter 1532751537994342401 5 Twitter 1532751537994342401
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, I Join us @ASCO 2022. LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
#2561-Developmental Therapeutics—Immunotherapy
Sunday, June 5, 8-11:00 AM CDT

Reply on Twitter 1530217104867196928 Retweet on Twitter 1530217104867196928 Like on Twitter 1530217104867196928 3 Twitter 1530217104867196928
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, IL Join us at the @ASCO 2022. Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance.
#376244-Developmental Therapeutics—Immunotherapy Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530216482998734850 Retweet on Twitter 1530216482998734850 Like on Twitter 1530216482998734850 3 Twitter 1530216482998734850
Avatar OmniSeq @omniseq ·
27 May

June 3-7 | Chicago, IL Join us at the 2022 ASCO Annual Meeting.
Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC.
#2623 -Developmental Therapeutics—Immunotherapy
Sunday, June 5, 2022, 8:00 AM -11:00 AM CDT

Reply on Twitter 1530215721862680578 Retweet on Twitter 1530215721862680578 Like on Twitter 1530215721862680578 1 Twitter 1530215721862680578
Avatar OmniSeq @omniseq ·
5 May

Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz

Reply on Twitter 1522266608911142917 Retweet on Twitter 1522266608911142917 Like on Twitter 1522266608911142917 6 Twitter 1522266608911142917
Load More...

  • Facebook
  • Twitter
©2022 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .